Interferon in chronic myeloid leukemia - A workshop report

M. Griesshammer, R. Hehlmann, A. Hochhaus, M. Talpaz, S. Tura, P. Stryckmans, N. C. Allan, J. Tanzer, H. J. Kolb, H. Heimpel

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The therapeutic efficacy of interferon-alpha (IFN-α) in the treatment of chronic myeloid leukemia is currently being tested in a number of institutional, interinstitutional, and international trials. There is no doubt that responses are achieved in many patients, and in a small subset complete eradication of clonogenic cells may be possible. However, it has not yet been shown that overall survival of patients treated with IFN-α is better than that of those treated with conventional cytoreductive drugs. There are still controversial opinions on problems such as dosages and duration of treatment, combination with cytostatic agents, definition of responses, and relevance of cytogenic and molecular data. An international workshop discussed the data on interferon therapy and attempted to define the role of interferon today in the management of chronic myeloid leukemia.

Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalAnnals of Hematology
Volume67
Issue number2
DOIs
StatePublished - Aug 1993
Externally publishedYes

Keywords

  • Bone marrow transplantation
  • Busulfan
  • Chronic myeloid leukemia
  • Hydroxyurea
  • Interferon

Fingerprint

Dive into the research topics of 'Interferon in chronic myeloid leukemia - A workshop report'. Together they form a unique fingerprint.

Cite this